TRVI

Trevi Therapeutics Inc

TRVI.US trevitherapeutics.com + Research + Basket
CIK 0001563880
Employees 34
Phone 203 304 2499
Fiscal year end December
IPO May 07, 2019
Address 195 Church Street, New Haven, CT, United States, 06510
13.81
+0.29 (+2.15%)
USD · NASDAQ
52-week range
9.82
20.22
Trading at 38% of the 52-week range
Market Cap
1.97B
P/E Ratio
0.00
Forward P/E
0.00
Book Value
2.26
Div. Yield
N/A
% Institutions
109.83%
% Insiders
0.628%

1 Year

+30.5%

3 Year

+654.6%

10 Year

+75.0%
Description

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Actions

Add an action for TRVI.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Ms. Jennifer L. Good Co-Founder, CEO, President, & Director 1965
Dr. James V. Cassella Ph.D. Chief Development Officer 1955
Dr. Farrell Simon Pharm.D. Chief Commercial Officer NA
Dr. Thomas R. Sciascia M.D. Co-Founder & Chief Scientific Officer 1953
Mr. David C. Hastings CPA Chief Financial Officer & Principal Financial Officer 1961
Mr. Christopher Galletta Controller & Chief Accounting Officer 1978
Katie McManus Communications Manager NA

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Mar 21, 2025 Jennifer L Good N/A Sale 5.26K $6.58 $34.63K SEC
Mar 10, 2025 Farrell Simon N/A Sale 81.31K $6.75 $548.86K SEC
Sep 09, 2024 Jennifer L Good N/A Sale 1.84K $3.04 $5.59K SEC
Sep 06, 2024 Jennifer L Good N/A Sale 4.22K $3.03 $12.78K SEC
Sep 04, 2024 Jennifer L Good N/A Sale 10.98K $3.02 $33.16K SEC
Aug 27, 2024 David P Meeker N/A Sale 4.56K $2.93 $13.35K SEC
Aug 16, 2024 Thomas Sciascia N/A Sale 18.66K $2.76 $51.50K SEC
Aug 14, 2024 Thomas Sciascia N/A Sale 100.00 $2.75 $275.00 SEC
May 29, 2024 Thomas Sciascia N/A Sale 53.37K $2.55 $136.09K SEC
May 22, 2024 Lisa Delfini N/A Sale 4.35K $2.64 $11.48K SEC
May 20, 2024 Jennifer L Good N/A Sale 25.04K $2.86 $71.61K SEC
May 10, 2024 Jennifer L Good N/A Sale 4.58K $2.90 $13.28K SEC
Oct 11, 2023 Lisa Delfini N/A Sale 785.00 $2.02 $1.59K SEC
Sep 11, 2023 Lisa Delfini N/A Sale 711.00 $2.20 $1.56K SEC
Aug 11, 2023 Lisa Delfini N/A Sale 682.00 $2.36 $1.61K SEC
Jul 11, 2023 Lisa Delfini N/A Sale 687.00 $2.34 $1.61K SEC
Jun 12, 2023 Lisa Delfini N/A Sale 610.00 $2.64 $1.61K SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
NEA Management Company, LLC 13.22M Jun 30, 2026 9.28% $15.53 0.00%
FMR Inc 12.56M Jun 30, 2026 8.82% $0.01 56.29%
BlackRock Inc 11.16M Jun 30, 2026 7.83% $0.00 8.93%
Frazier Life Sciences Management, L.P. 9.94M Jun 30, 2026 6.98% $4.04 0.00%
Wellington Management Company LLP 5.68M Jun 30, 2026 3.99% $0.02 9.55%
Vanguard Capital Management, LLC 5.53M Jun 30, 2026 3.88% $0.00 11.09%
Vivo Capital, LLC 5.09M Jun 30, 2026 3.58% $8.68 0.00%
Woodline Partners LP 4.08M Jun 30, 2026 2.86% $0.24 307.81%
Vestal Point Capital LP 3.10M Jun 30, 2026 2.18% $1.35 43.09%
MPM Oncology Impact Management LP 3.07M Jun 30, 2026 2.16% $3.50 -6.82%
Frontier Capital Management CO Inc 3.07M Jun 30, 2026 2.16% $0.53 53.98%
Assenagon Asset Management SA 3.05M Jun 30, 2026 2.14% $0.04 0.00%
State Street Corp 3.03M Jun 30, 2026 2.12% $0.00 13.58%
Geode Capital Management, LLC 2.93M Jun 30, 2026 2.06% $0.00 5.39%
Marshall Wace Asset Management Ltd 2.67M Jun 30, 2026 1.88% $0.04 -32.57%
Eventide Asset Management, LLC 2.66M Jun 30, 2026 1.87% $0.66 1.44%
Rubric Capital Management LP 2.50M Jun 30, 2026 1.76% $0.43 -32.54%
AllianceBernstein L.P. 2.36M Jun 30, 2026 1.65% $0.01 -17.22%
Artia Global Partners LP 2.21M Jun 30, 2026 1.55% $7.61 9.80%
First Light Asset Management, LLC 2.10M Jun 30, 2026 1.47% $2.38 0.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard MStar Total Stk Mkt Idx Invest 4.61M 3.23% ▲ 13.47% Sep 30, 2026
2 iShares Russell 2000 ETF 2.82M 1.98% ▼ 1.14% Sep 30, 2026
3 Eventide Healthcare & Life Sciences I 2.66M 1.87% ▲ 1.44% Jun 30, 2026
4 Fidelity Select Biotechnology 2.37M 1.67% ▲ 0.00% Aug 31, 2026
5 Fidelity Small Cap Growth 1.95M 1.37% ▲ 0.00% Jul 31, 2026
6 Pictet-Biotech P USD 1.33M 0.93% ▲ 19.58% Jun 30, 2026
7 Fidelity Small Cap Index 1.17M 0.82% ▲ 0.87% Jul 31, 2026
8 MEDICAL BioHealth EUR Acc 1.09M 0.77% ▲ 0.02% Aug 31, 2026
9 Fidelity Growth Company Fund 1.04M 0.73% ▲ 0.00% Aug 31, 2026
10 iShares Russell 2000 Growth ETF 1.03M 0.72% ▼ 0.13% Sep 30, 2026

Financial Highlights

▼
Market Cap: $1.97B
EBITDA: $-59.42M
Book Value: $2.26
Earnings/Share: $-0.36
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -13.82%
ROE (TTM): -19.66%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Valuation Metrics

Enterprise Value: $1.61B
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 142.48M
Shares Float: 118.32M
% Insiders: 0.628%
% Institutions: 109.83%
Shares Short: 16.01M
Shares Short (Prior Month): 14.64M
Short Ratio: 5.94
Short % Float: 12.47%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$0.00
Cost of Goods Sold
adjust
$-132.00K
Gross Profit
subtotal
$-132.00K
SG&A
adjust
$-15.85M
R&D
adjust
$-33.48M
Operating Income
subtotal
$-49.33M
Other / Non-Operating Items
adjust
$6.57M
Net Income
subtotal
$-42.76M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about TRVI.US!